Peregrine flies with positive Phase II bavituximab lung cancer data
This article was originally published in Scrip
Executive Summary
Peregrine Pharmaceuticals was flying high with a 20% boost to its share price after it reported positive preliminary results from a Phase II trial of its first-in-class phosphatidylserine inhibitor, bavituximab, in non-small cell lung cancer (NSCLC).